<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04277637</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-11417-101</org_study_id>
    <nct_id>NCT04277637</nct_id>
  </id_info>
  <brief_title>Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies</brief_title>
  <official_title>A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability; and to define the maximum&#xD;
      tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D); and to evaluate the safety and&#xD;
      tolerability of the ramp-up dosing schedule and at the RP2D of BGB-11417 monotherapy, and&#xD;
      when given in combination with zanubrutinib.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 24, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to 30 days after the last dose of study drug, an average of 18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 30 days after the last dose of study drug, an average of 18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing Adverse Events (AEs) leading to discontinuation of BGB-11417</measure>
    <time_frame>Up to 30 days after the last dose of study drug, an average of 18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1, Part 3: Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Day 1 to 21 days target dose of the study drug, an average of 18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1, Part 3: Maximum RP2D of BGB-11417</measure>
    <time_frame>Day 1 to last dose of study drug, an average of 18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1, Part 3: Number of participants experiencing tumor lysis syndrome (TLS) relevant events</measure>
    <time_frame>Up to 30 days after the last dose of study drug, an average of 18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve from Time 0 to the Last Quantifiable Concentration (AUC0-last) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-âˆž) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Taken for Half the Initial Dose Administered to Be Eliminated from The Body (T1/2) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vz/F) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady State Area Under the Concentration-Time Curve of 0 - Last Day (AUCLast, ss) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3, Part 4: Steady State Area Under the Concentration-Time Curve of 0 - Last Day (AUCLast, ss) of zanubrutinib</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady State Maximum Observed Plasma Concentration (Cmax, ss) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3, Part 4: Steady State Maximum Observed Plasma Concentration (Cmax, ss) of zanubrutinib</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady State Trough Observed Plasma Concentration (Ctrough, SS) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3, Part 4: Steady State Trough Observed Plasma Concentration (Ctrough, SS) of zanubrutinib</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady State Time to Maximum Plasma Concentration (Tmax, ss) of BGB-11417</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3, Part 4: Steady State Time to Maximum Plasma Concentration (Tmax, ss) of zanubrutinib</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: AUC of BGB-11417 administered after a high fat/calorie meal (HF-Fed)</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmax of BGB-11417 administered after a high fat/calorie meal (HF-Fed)</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2, Part 4: Overall Response Rate (ORR) as Assessed by the Investigator</measure>
    <time_frame>Up to 30 days after the last dose of study drug, an average of 18 months</time_frame>
    <description>ORR is defined as the proportion of participants who had confirmed complete response Complete Response (CR) or Partial Response (PR)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">284</enrollment>
  <condition>Mature B-Cell Malignancies</condition>
  <arm_group>
    <arm_group_label>BGB-11417 Monotherapy Dose Finding: Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) including follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL) or transformed NHL; chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with low tumor burden or low creatine clearance; CLL/SLL with without high tumor burden or low creatine clearance will receive oral BGB-11417 until the maximum tolerated dose (MTD) (or maximum ascending dose (MAD)) and recommended phase 2 dose can be determined</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BGB-11417 Monotherapy Expansion Cohorts: Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with R/R indolent NHL including FL, MZL; aggressive NHL including DLBCL, transformed NHL; CLL/SLL with low tumor burden or low creatine clearance; CLL/SLL with without high tumor burden or low creatine clearance will receive oral BGB-11417 at the RP2D dose to further define the safety profile</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BGB-11417 + Zanubrutinib Combination Therapy Dose Finding: Part 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with R/R indolent NHL including FL, MZL; aggressive NHL including DLBCL, transformed NHL; CLL/SLL with low tumor burden or low creatine clearance; CLL/SLL with without high tumor burden or low creatine clearance will receive oral BGB-11417 until RP2D can be determined in combination with zanubrutinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BGB-11417 + Zanubrutinib Combination Therapy Dose Expansion: Part 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with R/R indolent NHL including FL, MZL; aggressive NHL including DLBCL, transformed NHL; CLL/SLL with low tumor burden or low creatine clearance; CLL/SLL with without high tumor burden or low creatine clearance will receive oral BGB-11417 at the RP2D dose to further define the safety profile in combination with zanubrutinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-11417</intervention_name>
    <description>Film-coated tablets administered once daily at a dose as specified in the treatment arm</description>
    <arm_group_label>BGB-11417 + Zanubrutinib Combination Therapy Dose Expansion: Part 4</arm_group_label>
    <arm_group_label>BGB-11417 + Zanubrutinib Combination Therapy Dose Finding: Part 3</arm_group_label>
    <arm_group_label>BGB-11417 Monotherapy Dose Finding: Part 1</arm_group_label>
    <arm_group_label>BGB-11417 Monotherapy Expansion Cohorts: Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zanubrutinib</intervention_name>
    <description>320 mg administered as twice-daily zanubrutinib should be administered as two 80-mg capsules twice a day (160 mg twice a day) or oOnce-daily zanubrutinib should be administered as four 80-mg capsules once a day (320 mg once a day)</description>
    <arm_group_label>BGB-11417 + Zanubrutinib Combination Therapy Dose Expansion: Part 4</arm_group_label>
    <arm_group_label>BGB-11417 + Zanubrutinib Combination Therapy Dose Finding: Part 3</arm_group_label>
    <other_name>BGB-A317</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed diagnosis of one of the following:&#xD;
&#xD;
             NHL Cohorts:&#xD;
&#xD;
             a. MZL i. R/R extranodal, splenic, or nodal MZL defined as disease that relapsed&#xD;
             after, or was refractory to, at least two prior therapies ii. Active disease requiring&#xD;
             treatment&#xD;
&#xD;
             b. FL i. R/R FL (Grade 1, 2 or 3a based on the WHO 2008 classification of tumors of&#xD;
             hematopoietic and lymphoid tissue) and defined as disease that relapsed after, or was&#xD;
             refractory to, at least 2 prior systemic therapies&#xD;
&#xD;
             c. DLBCL i. R/R DLBCL (including all subtypes of DLBCL) defined as disease that&#xD;
             relapsed after, or was refractory to, at least two prior systemic therapies and has&#xD;
             either progressed following or is not a candidate for autologous stem cell transplant&#xD;
             (due to comorbidities or non-responsiveness to salvage chemotherapy)&#xD;
&#xD;
             d. Transformed indolent B-cell NHL i. Any lymphoma otherwise eligible for Part 1 that&#xD;
             has transformed into a more aggressive lymphoma. Patients with transformation from CLL&#xD;
             or SLL (Richter's transformation) are not eligible for Part 1.&#xD;
&#xD;
             CLL/SLL Cohorts:&#xD;
&#xD;
             e. CLL/SLL diagnosis that meets the International Workshop on Chronic Lymphocytic&#xD;
             Leukemia (IWCLL) criteria i. Disease characterized as R/R disease defined as disease&#xD;
             that relapsed after, or was refractory to, at least 2 prior therapies ii. Requiring&#xD;
             treatment as defined by history&#xD;
&#xD;
             MCL cohorts:&#xD;
&#xD;
             For Australia and New Zealand only:&#xD;
&#xD;
             f. WHO-defined MCL I. R/R MCL defined as disease that relapsed after, or was&#xD;
             refractory to, at least 1 prior systemic therapy; ii. Requiring treatment in the&#xD;
             opinion of the investigatorr&#xD;
&#xD;
             WM cohorts:&#xD;
&#xD;
             For Australia and New Zealand only:&#xD;
&#xD;
             g. WHO-defined WM (clinical and definitive histologic diagnosis) i. R/R disease&#xD;
             defined as disease that relapsed after, or was refractory to, at least 1 prior&#xD;
             therapy; ii. Meeting at least 1 criterion for treatment according to consensus panel&#xD;
             criteria from the Seventh International Workshop on WaldenstrÃ¶m's Macroglobulinemia&#xD;
             (Dimopoulos et al 2014)&#xD;
&#xD;
          2. Measurable disease by computed tomography (CT)/magnetic resonance imaging (MRI),&#xD;
             defined as:&#xD;
&#xD;
               1. CLL: at least 1 lymph node &gt; 1.5 cm in longest diameter and measurable in 2&#xD;
                  perpendicular dimensions or clonal lymphocytes measured by flow cytometry&#xD;
&#xD;
               2. DLBCL, FL, MZL, SLL: at least 1 lymph node &gt; 1.5 cm in longest diameter OR 1&#xD;
                  extranodal lesion &gt; 1.0 cm in the longest diameter, measurable in at least 2&#xD;
                  perpendicular dimensions. For MZL, isolated splenomegaly is considered measurable&#xD;
                  for this study&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2&#xD;
&#xD;
          4. Adequate organ function&#xD;
&#xD;
          5. Adequate pancreatic function indicated by:&#xD;
&#xD;
               1. Serum amylase â‰¤ 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
               2. Serum lipase â‰¤ 1.5 x ULN&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Known central nervous system involvement by lymphoma/leukemia&#xD;
&#xD;
          2. Known plasma cell neoplasm, prolymphocytic leukemia, history of or currently suspected&#xD;
             Richter's syndrome&#xD;
&#xD;
          3. Prior therapy â‰¥ 2 months with or progression on a B-cell lymphoma-2 (Bcl-2) inhibitor&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Simpson</last_name>
    <role>Study Director</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BeiGene</last_name>
    <phone>1-877-828-5568</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Concord Repatriation General Hospital</name>
      <address>
        <city>Concord</city>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter McCallum Cancer Center</name>
      <address>
        <city>Melbourne</city>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Nedlands</city>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NHL</keyword>
  <keyword>BCL2 Inhibitor</keyword>
  <keyword>CLL</keyword>
  <keyword>MCL</keyword>
  <keyword>MZL</keyword>
  <keyword>SLL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zanubrutinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

